Which has stronger valuation and earnings, TLX or HALO?

Halozyme Therapeutics has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.91 -$7.12M N/A N/A Halozyme Therapeutics $1.40B 8.19 $316.89M $3.93 25.51

Which has stronger earnings and valuation, KYMR or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 277.75 -$311.35M -$3.62 N/A Telix Pharmaceuticals $803.79M 3.91 -$7.12M N/A N/A

Which has preferable valuation & earnings, TLX or BMRN?

BioMarin Pharmaceutical has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.91 -$7.12M N/A N/A BioMarin Pharmaceutical $3.22B 3.44 $348.90M -$0.10 N/A

Which has higher valuation and earnings, TLX or TGTX?

TG Therapeutics has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.91 -$7.12M N/A N/A TG Therapeutics $616.29M 15.82 $447.18M $0.66 97.74

Which has higher earnings & valuation, MDGL or TLX?

Telix Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Madrigal Pharmaceuticals $1.43B 6.95 -$288.28M -$5.98 N/A Telix Pharmaceuticals $803.79M 3.91 -$7.12M N/A N/A

Telix Pharmaceuticals (TLX) Competitors

$9.23 -0.13 (-1.39%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$9.10 -0.13 (-1.35%)

As of 11/13/2026 07:30 PM Eastern

Compare

TLX vs. HALO, KYMR, BMRN, TGTX, and MDGL

Should you buy Telix Pharmaceuticals stock or one of its competitors? Telix Pharmaceuticals's main competitors and comparable companies include Halozyme Therapeutics (HALO), Kymera Therapeutics (KYMR), BioMarin Pharmaceutical (BMRN), TG Therapeutics (TGTX), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Telix Pharmaceuticals compare to Halozyme Therapeutics?

Telix Pharmaceuticals (NASDAQ:TLX) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Halozyme Therapeutics has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.91	-$7.12M	N/A	N/A
Halozyme Therapeutics	$1.40B	8.19	$316.89M	$3.93	25.51

Halozyme Therapeutics has a net margin of 26.93% compared to Telix Pharmaceuticals' net margin of 0.00%. Halozyme Therapeutics' return on equity of 751.81% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Halozyme Therapeutics	26.93%	751.81%	23.84%

In the previous week, Halozyme Therapeutics had 12 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 1 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.82 beat Halozyme Therapeutics' score of 0.13 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telix Pharmaceuticals	Very Positive
Halozyme Therapeutics	Neutral

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Telix Pharmaceuticals has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Telix Pharmaceuticals presently has a consensus target price of $20.50, indicating a potential upside of 122.10%. Halozyme Therapeutics has a consensus target price of $108.18, indicating a potential upside of 7.89%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Halozyme Therapeutics	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

Halozyme Therapeutics beats Telix Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Telix Pharmaceuticals has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Telix Pharmaceuticals' return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-22.39%	-20.48%
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Kymera Therapeutics had 3 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 4 mentions for Kymera Therapeutics and 1 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.82 beat Kymera Therapeutics' score of 1.07 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Kymera Therapeutics	Positive
Telix Pharmaceuticals	Very Positive

Kymera Therapeutics presently has a consensus price target of $139.16, suggesting a potential upside of 9.09%. Telix Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 122.10%. Given Telix Pharmaceuticals' higher probable upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.89
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Kymera Therapeutics has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	277.75	-$311.35M	-$3.62	N/A
Telix Pharmaceuticals	$803.79M	3.91	-$7.12M	N/A	N/A

Summary

Telix Pharmaceuticals beats Kymera Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

Telix Pharmaceuticals (NASDAQ:TLX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Telix Pharmaceuticals has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.91	-$7.12M	N/A	N/A
BioMarin Pharmaceutical	$3.22B	3.44	$348.90M	-$0.10	N/A

Telix Pharmaceuticals has a net margin of 0.00% compared to BioMarin Pharmaceutical's net margin of -0.52%. BioMarin Pharmaceutical's return on equity of 5.58% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
BioMarin Pharmaceutical	-0.52%	5.58%	3.51%

In the previous week, BioMarin Pharmaceutical had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 9 mentions for BioMarin Pharmaceutical and 1 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.82 beat BioMarin Pharmaceutical's score of 0.35 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telix Pharmaceuticals	Very Positive
BioMarin Pharmaceutical	Neutral

Telix Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 122.10%. BioMarin Pharmaceutical has a consensus target price of $87.22, suggesting a potential upside of 52.40%. Given Telix Pharmaceuticals' higher probable upside, equities analysts clearly believe Telix Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.80

Summary

BioMarin Pharmaceutical beats Telix Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to TG Therapeutics?

Telix Pharmaceuticals (NASDAQ:TLX) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Telix Pharmaceuticals currently has a consensus target price of $20.50, indicating a potential upside of 122.10%. TG Therapeutics has a consensus target price of $63.00, indicating a potential downside of 2.34%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Telix Pharmaceuticals is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
TG Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

TG Therapeutics has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.91	-$7.12M	N/A	N/A
TG Therapeutics	$616.29M	15.82	$447.18M	$0.66	97.74

58.6% of TG Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Telix Pharmaceuticals has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

TG Therapeutics has a net margin of 11.81% compared to Telix Pharmaceuticals' net margin of 0.00%. TG Therapeutics' return on equity of 18.82% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
TG Therapeutics	11.81%	18.82%	7.78%

In the previous week, TG Therapeutics had 26 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 27 mentions for TG Therapeutics and 1 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.82 beat TG Therapeutics' score of 0.42 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telix Pharmaceuticals	Very Positive
TG Therapeutics	Neutral

Summary

TG Therapeutics beats Telix Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Telix Pharmaceuticals (NASDAQ:TLX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Telix Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -10.89%. Telix Pharmaceuticals' return on equity of 0.00% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-10.89%	-27.08%	-12.04%
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Madrigal Pharmaceuticals had 13 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 14 mentions for Madrigal Pharmaceuticals and 1 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.82 beat Madrigal Pharmaceuticals' score of 0.26 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Madrigal Pharmaceuticals	Neutral
Telix Pharmaceuticals	Very Positive

Telix Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$1.43B	6.95	-$288.28M	-$5.98	N/A
Telix Pharmaceuticals	$803.79M	3.91	-$7.12M	N/A	N/A

Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its stock price is 198% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

Madrigal Pharmaceuticals currently has a consensus target price of $706.87, suggesting a potential upside of 65.39%. Telix Pharmaceuticals has a consensus target price of $20.50, suggesting a potential upside of 122.10%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Telix Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.19B	$4.15B	$7.87B	$12.20B
Dividend Yield	N/A	3.62%	2.46%	4.53%
P/E Ratio	N/A	24.48	34.56	30.65
Price / Sales	3.91	16.43	8.62	5.84
Price / Cash	221.99	26.37	21.93	22.49
Price / Book	7.50	4.00	4.35	3.76
Net Income	-$7.12M	-$22.86M	$3.52B	$390.95M
7 Day Performance	-4.15%	-2.82%	-1.52%	-0.34%
1 Month Performance	-12.68%	-5.39%	-3.54%	-5.79%
1 Year Performance	-1.18%	-1.71%	1.45%	-5.71%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	4.7805 of 5 stars	$9.23 -1.4%	$20.50 +122.1%	N/A	$3.19B	$803.79M	N/A	1,184	Positive News
HALO Halozyme Therapeutics	4.1131 of 5 stars	$103.61 +0.7%	$106.73 +3.0%	N/A	$11.76B	$1.40B	26.36	423	Analyst Downgrade
KYMR Kymera Therapeutics	1.9849 of 5 stars	$137.13 -1.2%	$139.16 +1.5%	N/A	$11.73B	$39.21M	N/A	285
BMRN BioMarin Pharmaceutical	4.2299 of 5 stars	$56.79 -0.7%	$87.91 +54.8%	N/A	$11.04B	$3.22B	N/A	3,221	Analyst Forecast
TGTX TG Therapeutics	1.8282 of 5 stars	$65.69 +3.6%	$63.00 -4.1%	N/A	$10.11B	$616.29M	24.11	399	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 11/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. HALO, KYMR, BMRN, TGTX, and MDGL

How does Telix Pharmaceuticals compare to Halozyme Therapeutics?

Summary

How does Telix Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

How does Telix Pharmaceuticals compare to TG Therapeutics?

Summary

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. HALO, KYMR, BMRN, TGTX, and MDGL

How does Telix Pharmaceuticals compare to Halozyme Therapeutics?

Which has stronger valuation and earnings, TLX or HALO?

Is TLX or HALO more profitable?

Does the media prefer TLX or HALO?

Do institutionals & insiders believe in TLX or HALO?

Which has more risk and volatility, TLX or HALO?

Do analysts prefer TLX or HALO?

Summary

How does Telix Pharmaceuticals compare to Kymera Therapeutics?

Is KYMR or TLX more profitable?

Does the media prefer KYMR or TLX?

Do analysts recommend KYMR or TLX?

Which has more volatility & risk, KYMR or TLX?

Which has stronger earnings and valuation, KYMR or TLX?

Summary

How does Telix Pharmaceuticals compare to BioMarin Pharmaceutical?

Do institutionals & insiders hold more shares of TLX or BMRN?

Which has more volatility and risk, TLX or BMRN?

Which has preferable valuation & earnings, TLX or BMRN?

Is TLX or BMRN more profitable?

Does the media refer more to TLX or BMRN?

Do analysts recommend TLX or BMRN?

Summary

How does Telix Pharmaceuticals compare to TG Therapeutics?

Do analysts prefer TLX or TGTX?

Which has higher valuation and earnings, TLX or TGTX?

Do institutionals and insiders believe in TLX or TGTX?

Which has more risk & volatility, TLX or TGTX?

Is TLX or TGTX more profitable?

Does the media favor TLX or TGTX?

Summary

How does Telix Pharmaceuticals compare to Madrigal Pharmaceuticals?

Do insiders & institutionals have more ownership in MDGL or TLX?

Is MDGL or TLX more profitable?

Does the media favor MDGL or TLX?

Which has higher earnings & valuation, MDGL or TLX?

Which has more risk & volatility, MDGL or TLX?

Do analysts rate MDGL or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools